Protective effect of atorvastatin in cultured osteoarthritic chondrocytes

Journal of Orthopaedic Research

Volumn 28, Issue 1, 2010, Pages 110-115

  Simopoulou, Theodora ^a   Malizos, Konstantinos N ^a,b   Poultsides, Lazaros ^a   Tsezou, Aspasia ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b Institute for Biomedical Research and Technology   (Greece)

Author keywords

Atorvastatin; Chondrocytes; MMP 13; Osteoarthritis

Indexed keywords

AGGRECAN; ATORVASTATIN; COLLAGEN TYPE 2; COLLAGENASE 3; FARNESOL; GERANYLGERANIOL; INTERLEUKIN 1BETA; MESSENGER RNA; SQUALENE;

ADULT; AGED; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL VIABILITY; CHONDROPROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AGGRECANS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; COLLAGEN TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1BETA; KNEE JOINT; MALE; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PYRROLES;

EID: 73249146659     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20953     Document Type: Article

References (26)

1. Mehta JL, Chen J, Hermonat PL, et al. 2006. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 69:36-45.
2. Rutsch F, Terkeltaub R. 2005. Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. Joint Bone Spine 72:110-118.
3. Aspden RM, Scheven BA, Hutchison JD. 2001. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet 357:1118-1120.
4. Kellgren JH. 1961. Osteoarthrosis in patients and populations. BMJ 1:1-6.
5. Hart DJ, Doyle DV, Spector TD. 1995. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol 22:1118-1123.
6. Stürmer T, Sun Y, Sauerland S, et al. 1998. Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. J Rheumatol 25:1827-1832.
7. Endo A. 1992. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569-1582.
8. Bellosta S, Via D, Canavesi M, et al. 1998. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678.
9. Luan Z, Chase AJ, Newby AC. 2003. Statins inhibit secretion of metalloproteinases -1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Atheroscl Throm Vas 23:769-775.
10. Thunyakitpisal PD, Chaisuparat R. 2004. Simvastatin, an HMG-Coa reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 94:403-409.
11. Lazzerini PE, Capecchi PL, Nerucci F, et al. 2004. Simvastatin reduces MMP-3 level in interleukin 1β stimulated human chondrocyte culture. Ann Rheum Dis 63:867-869.
12. Leung BP, Sattar N, Crilly A, et al. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524-1530.
13. Lazzerini PE, Lorenzini S, Selvi E, et al. 2007. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukine 1β-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheum 25:696-700.
14. Yokota K, Miyazaki T, Hirano M, et al. 2006. Simvastatin inhibits the production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 33:463-471.
15. Dombrecht EJ, Van Offel JF, Bridts CH, et al. 2007. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin Exp Rheumatol 25:534-539.
16. Corsini A, Bellosta S, Baetta R, et al. 1999. New insight into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428.
17. Burrage PS, Mix KS, Brinckerhoff CE. 2006. Matrix metalloproteinases: role in arthritis. Front Biosci 11:529-543.
18. Forsyth CB, Cole A, Murphy G, et al. 2005. Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci 60:1118-1124.
19. van den Berg WB. 1999. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Z Rheumatol 58:136-141.
20. Takaishi H, Kimura T, Dalal S, et al. 2008. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 9:47-54.
21. Akasaki Y, Matsuda S, Nakayama K, et al. 2009. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 17:235-243.
22. Mason RP, Walter MF, Day CA, et al. 2005. Intramolecular differences of 3-hydroxy-3methylglutaryl coenzyme areductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11F-23F.
23. Hatano H, Maruo A, Bolander ME, et al. 2003. Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci 8:842-848.
24. Zhang H, Lin CY. 2008. Simvastatin stimulates chondrogenic phenotype of intervertebral disc cells partially through BMP-2 pathway. Spine 33:E525-E531.
25. Inoue I, Goto S, Mizotani K, et al. 2000. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferators-activated receptor a (PPARa) in primary endothelial cells. Life Sci 67:863-876.
26. Abeles AM, Marjanovic N, Park J, et al. 2007. Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts. Effects of statins and farnesyl and geranylgeranyl transferase inhibitors. Arthritis Rheum 56:2840-2853.